Valion Bio, Inc. - Common stock (VBIO)

Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors.

SAN ANTONIO, TX / ACCESS Newswire / August 27, 2026 / Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of common stock. The purpose of the reverse stock split is to bring the Company into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market ("Nasdaq").

Aug. 14, 2026 — Kartoon Studios, Inc. (NYSE: TOON), a global children’s and family entertainment company, reported second-quarter 2026 financial results while outlining a strategic transformation centered on the ownership, development and commercialization of high-value intellectual property.

Potential Fourth-Quarter 2026 Decision Could Mark Entolimod's First National Registration and Open a Pathway to Strategic Stockpiling and Government Procurement

AFRRI/NIAID Program to Advance Safety and Therapeutic Studies in Rapid Sequence; Top-Line Therapeutic Data Expected in Early Fall